The past year has seen a multitude of FDA approvals, ranging from IL-23 and JAK inhibitors to biologics and subcutaneous treatment administrations, that have helped redefine what it means to treat IBD.
Experts review best practices around plan design that payers and plan sponsors should address as more interchangeable biosimilars potentially enter the market.